Compare PAGSEG Inc (PAGS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Regeneron Pharmaceuticals Inc — how do they compare? PAGSEG Inc trades at $9.74 (market cap $2.68B), while Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 26.4× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.86%). Which is the better fit depends on your goals.
| PAGS | REGN | |
|---|---|---|
Market Cap | $2.68B | $70.79B |
Sector | Technology | Health |
52-Week High | $12.00 | $812.27 |
52-Week Low | $7.75 | $545.46 |
Enterprise Value | $10.42B | $64.74B |
Dividend Yield | 10.86% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $9.29, up 2.77% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 6.57 and P/S of 0.68, trading below book value. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 2026 missing estimates. The company maintains strong profitability with 10.4% net margin and robust cash flow generation of $7.56B from operations in 2025.
Analyst consensus remains strongly bullish with 62.5% buy ratings, though Brazilian macroeconomic risks and competitive pressures warrant monitoring. The stock presents value opportunity with deep discount valuation while benefiting from Brazil's digital banking growth, though execution on credit expansion and funding costs remain key catalysts.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
